Trial Outcomes & Findings for Exploration of Pupil Dilation in Horner's Patients Taking Flomax (NCT NCT03615508)
NCT ID: NCT03615508
Last Updated: 2022-03-03
Results Overview
pupil dilation measurements will be taken of each eye at the eye examination.
Recruitment status
TERMINATED
Study phase
PHASE4
Target enrollment
1 participants
Primary outcome timeframe
20-30 minutes after 10% phenylephrine has been placed in each eye.
Results posted on
2022-03-03
Participant Flow
Participant milestones
| Measure |
10% Phenylephrine
All patients will receive 10% phenylephrine at their eye examination as the drug to dilate the pupil. After pupil dilation, pupil size will be measured.
10% phenylephrine: 10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.
|
|---|---|
|
Overall Study
STARTED
|
1
|
|
Overall Study
COMPLETED
|
1
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Exploration of Pupil Dilation in Horner's Patients Taking Flomax
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 20-30 minutes after 10% phenylephrine has been placed in each eye.Population: Study incomplete. Only 1 subject enrolled and data not reported for 1 participant for privacy reasons.
pupil dilation measurements will be taken of each eye at the eye examination.
Outcome measures
Outcome data not reported
Adverse Events
10% Phenylephrine
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place